MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ajt.12280

Медицинская библиотека · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013

Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study.

Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar H J, Beckebaum S, Jonas S, Sudan D, Fischer L, Duvoux C, Chavin K D, Koneru B, Huang M A, Chapman W C, Foltys D, Dong G, Lopez P M, Fung J, Junge G, H2304 Study Group

Сравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

In a 24-month prospective, randomized, multicenter, open-label study, de novo liver transplant patients were randomized at 30 days to everolimus (EVR) + Reduced tacrolimus (TAC; n = 245), TAC Control (n = 243) or TAC Elimination (n = 231). Randomization to TAC Elimination was stopped prematurely due to a significantly higher rate of treated biopsy-proven acute rejection (tBPAR). The incidence of the primary efficacy endpoint, composite efficacy failure rate of tBPAR, graft loss or death postrandomization was similar with EVR + Reduced TAC (10.3%) or TAC Control (12.5%) at month 24 (difference -2.2%, 97.5% confidence interval [CI] -8.8%, 4.4%). BPAR was less frequent in the EVR + Reduced TAC group (6.1% vs. 13.3% in TAC Control, p = 0.010). Adjusted change in estimated glomerular filtration rate (eGFR) from randomization to month 24 was superior with EVR + Reduced TAC versus TAC Control: difference 6.7 mL/min/1.73 m(2) (97.5% CI 1.9, 11.4 mL/min/1.73 m(2), p = 0.002). Among patients who remained on treatment, mean (SD) eGFR at month 24 was 77.6 (26.5) mL/min/1.73 m(2) in the EVR + Reduced TAC group and 66.1 (19.3) mL/min/1.73 m(2) in the TAC Control group (p < 0.001). Study medication was discontinued due to adverse events in 28.6% of EVR + Reduced TAC and 18.2% of TAC Control patients. Early introduction of everolimus with reduced-exposure tacrolimus at 1 month after liver transplantation provided a significant and clinically relevant benefit for renal function at 2 years posttransplant.

Для цитирования: Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar H J, Beckebaum S, Jonas S, Sudan D, Fischer L, Duvoux C, Chavin K D, Koneru B, Huang M A, Chapman W C, Foltys D, Dong G, Lopez P M, Fung J, Junge G, H2304 Study Group. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study.. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013. DOI: 10.1111/ajt.12280.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.